|
gptkbp:instanceOf
|
gptkb:receptor_tyrosine_kinase
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:Japan
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE36
|
|
gptkbp:brand
|
gptkb:Alecensa
|
|
gptkbp:CASNumber
|
1256580-46-7
|
|
gptkbp:developedBy
|
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:eliminationHalfLife
|
32.5 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C30H34N4O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
alectinib
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Roche
|
|
gptkbp:mechanismOfAction
|
inhibits ALK phosphorylation
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
gptkb:DB11363
49806724
|
|
gptkbp:sideEffect
|
gptkb:anemia
edema
constipation
fatigue
myalgia
increased liver enzymes
|
|
gptkbp:synonym
|
gptkb:CH5424802
|
|
gptkbp:target
|
gptkb:ALK
|
|
gptkbp:UNII
|
D6FZ7R4S2F
|
|
gptkbp:usedFor
|
gptkb:non-small_cell_lung_cancer
|
|
gptkbp:bfsParent
|
gptkb:ALK_rearrangement
|
|
gptkbp:bfsLayer
|
5
|